bosentan anhydrous has been researched along with Bile Duct Obstruction, Intrahepatic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fattinger, K; Funk, C; Meier, PJ; Pantze, M; Reichen, J; Stieger, B; Weber, C | 1 |
| Hagihara, Y; Sonoi, R | 1 |
2 other study(ies) available for bosentan anhydrous and Bile Duct Obstruction, Intrahepatic
| Article | Year |
|---|---|
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
Topics: Animals; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Bile Canaliculi; Bosentan; Cholestasis, Intrahepatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Endothelin Receptor Antagonists; Glyburide; Humans; Hypertension; Liver; Male; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sulfonamides; Taurocholic Acid | 2001 |
Switching of cell fate through the regulation of cell growth during drug-induced intrahepatic cholestasis.
Topics: Amides; Bosentan; Cell Line; Cell Proliferation; Cholestasis, Intrahepatic; Humans; Pyridines | 2020 |